Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Advantage

Neither a doctor nor a teaching hospital

Research payments

$12,962,663

588 payments

Through program year 2025, Clinical Research Advantage is reported as receiving $12,962,663 in research payments, across 588 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $436,011 17
2024 Research $778,531 21
2023 Research $1,247,240 55
2022 Research $3,230,641 109
2021 Research $4,695,862 200
2020 Research $2,070,564 93
2019 Research $503,813 93

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $12,568,679 486 payments
  2. Allergan Inc. $299,029 72 payments
  3. Novartis Pharmaceuticals Corporation $41,312 4 payments
  4. Eli Lilly Export S.A. Puerto Rico Branch $33,087 22 payments
  5. Sandoz Inc. $19,956 3 payments
  6. Shionogi Inc $600 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $6,041,027 74 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,192,758 23 payments
  3. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $453,730 9 payments
  4. Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $436,652 23 payments
  5. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain $407,926 29 payments
  6. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (Nash) $398,689 33 payments
  7. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3016859 for the Treatment of Osteoarthritis $392,442 27 payments
  8. A Master Protocol for Randomized Placebo-Controlled Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain $325,490 6 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $325,172 9 payments
  10. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3016859 for the Treatment of Chronic Low Back Pain $317,090 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record